



PDAB prescription drug review schedule for 2026

PDAB meeting date	Prescription drug	Main treatment
June 17	Jardiance	Type 2 diabetes
June 17	Mounjaro	Type 2 diabetes
June 17	Ozempic	Type 2 diabetes
June 17	Humulin R U-500 (concentrated and KwikPen)	Improve blood sugar control in adults and children with diabetes (Type 1 and Type 2) who require more than 200 units of insulin per day
July 15	Keytruda*	Cancer
July 15	Verzenio	Cancer
July 15	Xeljanz	Several autoimmune and inflammatory conditions
Aug. 19	Ocrevus	Multiple sclerosis (MS)
Aug. 19	Skyrizi*	Immune-mediated inflammatory conditions
Aug. 19	Tremfya	Plaque psoriasis
Aug. 19	Xolair	Allergic and inflammatory conditions in both adults and children
Sept. 16 and Oct. 21		The board will review all drugs and discuss recommendations for the annual report

*Indicates a designation of a drug for rare diseases or conditions



Provide feedback about the prescription drugs on this list

Scan the QR code to visit the website. Click on the feedback form and share your story. We have forms for patients and caregivers, medical professionals, clinics, manufacturers, and pharmacy benefit managers.

The board wants to hear from you!

You can also send a letter or speak at a board meeting. Scan the QR code, click on the public comment form, and request to speak or submit a letter. If you need assistance, email pdab@dcbs.oregon.gov or call 971-374-3724.